The latest development in the US onshoring trend—spurred by President Donald Trump—is Johnson & Johnson's announcement Friday morning of a massive $55 billion investment plan over the next four years to build manufacturing facilities and research infrastructure in the US.

J&J said the $55 billion in research, development, and technology investments represents a 25% increase compared to the previous four years and builds on its elevated US investment trends following Trump's 2017 Tax Cuts and Jobs Act.

"Today's announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world's toughest healthcare challenges," Joaquin Duato, Chairman and CEO of J&J, wrote in a press release. 

Duato said, "Our increased U.S. investment begins with the groundbreaking of a high-tech facility in North Carolina that will not only add U.S.-based jobs but also manufacture cutting-edge medicines to treat patients in America and around the world." 

In addition to the 500,000 square foot, state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which construction is already underway, J&J outlined its investment plans over Trump's second term: 

More color on the Wilson factory's economic benefit to the American worker and surrounding community: 

In addition to J&J, in recent days or weeks: 

The rise of US onshoring... This is America First.